In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beiersdorf prelim sales, earnings down in 2009

This article was originally published in The Rose Sheet

Executive Summary

Hamburg, Germany-based firm records preliminary sales of €5.7 bil. ($8.3 bil.) for fiscal 2009, down 3.6 percent from the year prior. Sales in its consumer business segment, which includes Eucerin and NIVEA brands, were down 2.2 percent to €5.01 bil. ($7.2 bil.), though organic sales of the unit increased 1.2 percent. Although sales in Western Europe declined, revenues in the U.S., China and Latin America rose. Profit after taxes fell 33 percent to €379 mil. ($544.8 mil.). Beiersdorf's final results for the fiscal year will be released at an analyst meeting March 4

You may also be interested in...



ASCO 2020: Roche Highlights TIGIT As Tecentriq Bags Another Approval

The Swiss major focused almost exclusively on the benefits of the combination of Tecentriq and its TIGIT inhibitor tiragolumab at ASCO but also celebrated the approval of a Tecentriq/Avastin combo for hepatocellular carcinoma.

Mylan Makes Decision On Potential First Botox Biosimilar

Mylan first announced plans to develop a biosimilar of the Botox cosmetic and therapeutic brands back in 2018 through an alliance with Revance Therapeutics. More than two years later, a verdict has been reached by the company.

Mylan Pulls Generic Gilenya Application Over Study Concerns

Separate concerns raised by the EMA over bioequivalence studies have led Mylan and Accord to withdraw generic applications, including the former’s generic version of Gilenya for the treatment of multiple sclerosis.

UsernamePublicRestriction

Register

SC142271

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel